These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 38003)

  • 1. Analogs of L-aspartic acid in chemotherapy for cancer.
    Jayaram HN; Cooney DA
    Cancer Treat Rep; 1979 Jun; 63(6):1095-108. PubMed ID: 38003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the antimetabolite of L-alanosine, L-alanosyl-5-amino-4-imidazolecarboxylic acid ribonucleotide, in tumors and assessment of its inhibition of adenylosuccinate synthetase.
    Tyagi AK; Cooney DA
    Cancer Res; 1980 Dec; 40(12):4390-7. PubMed ID: 7438071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
    Johnson RK; Inouye T; Goldin A; Stark GR
    Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
    Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
    Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
    Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
    Cooney DA; Karlowicz MG; Cubillan J; Roettger M; Jayaram HN
    Cancer Treat Rep; 1978 Oct; 62(10):1503-7. PubMed ID: 361225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
    Johnson RK; Swyryd EA; Stark GR
    Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
    [No Abstract]   [Full Text] [Related]  

  • 8. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
    Friedman J; Moore EC; Hall SW; Loo TL
    Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the aspartic acid binding site of Escherichia coli asparagine synthetase B using substrate analogs.
    Parr IB; Boehlein SK; Dribben AB; Schuster SM; Richards NG
    J Med Chem; 1996 Jun; 39(12):2367-78. PubMed ID: 8691431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of L-asparagine synthetase, in vitro.
    Cooney DA; Driscoll JS; Milman HA; Jayaram HN; Davis RD
    Cancer Treat Rep; 1976 Oct; 60(10):1493-557. PubMed ID: 14784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of pyrimidine biosynthesis and effect on proliferative growth of colonic cancer cells.
    Tsuboi KK; Edmunds NH; Kwong LK
    Cancer Res; 1977 Sep; 37(9):3080-7. PubMed ID: 884665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
    Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
    Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
    Creagan ET; O'Connell MJ; Kovach JS
    Cancer; 1983 Aug; 52(4):615-8. PubMed ID: 6861099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
    Kensler TW; Jayaram HN; Cooney DA
    Adv Enzyme Regul; 1982; 20():57-73. PubMed ID: 7113804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Kovach JS; Schutt AJ; Moertel CG; O'Connell MJ
    Cancer Treat Rep; 1979; 63(11-12):1909-12. PubMed ID: 526923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
    Monks A; Anderson LW; Strong J; Cysyk RL
    J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-(Phosphonacetyl)-L-aspartate (PALA): current status.
    Rozencweig M; Abele R; Piccart M; Von Hoff DD; Muggia FM
    Recent Results Cancer Res; 1980; 74():72-7. PubMed ID: 7444151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Embryotoxicity in mice of phosphonacetyl-L-aspartic acid (PALA), a new antitumor agent. II. Studies on its mechanism and reversibility.
    Sieber SM; Botkin CC; Leslie KA; Cooney DA
    Teratology; 1980 Dec; 22(3):321-8. PubMed ID: 7233337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B; Jayaram HN; Johnson RK
    Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
    Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.